

# Infliximab (REMICADE) – Induction + Maintenance Infusion Therapy Plan Orders

Page 1 of 3

Name:
Kaiser Permanente Member I.D. #
Date of Birth

### **Instructions to Provider**

Printed Name: \_\_\_\_

Review orders and note any changes. All orders with \( \subseteq \) will be placed unless otherwise noted. Please fax completed order form to the infusion center where the patient will be receiving treatment (see fax numbers at the end of this protocol).

Let orders are not included on this form - place orders via usual method. Let monitoring is the responsibility of the ordering physician.

Please complete all of the following:	ace orders via usual metriou. Lab mornioring is the responsibility of the ordering physician.				
· · · · · · · · · · · · · · · · · · ·					
☐ Pre-Service Authorization has been	obtained by Kaiser Permanente <b>Fax:</b> 1-888-282-2685 <b>Voice</b> : 1-800-289-1363				
Order Date:	Diagnosis: ICD-10 code (REQUIRED):				
Weight:kg	ICD-10 description				
<ul> <li>General Plan Communication</li> <li>Induction Schedule: Infuse inflixima</li> <li>Special instructions/notes:</li></ul>					
Provider Information					
<ul> <li>HBV cAb, sAg, and sAb.</li> <li>Ensure baseline PPD or quantiFER</li> <li>Ensure an immunization plan is in p</li> <li>Live vaccines should not be given c</li> </ul>					
Infusion Therapy					
Indicate rounded dose: ☐ 300 in Route: Intravenous  Frequency: Every 2 weeks x 2 do Infusion Rate: 10 − 1,100 mL/hr to 1  250 mL bag: Start in then 40 mL/hr for 1  250 mL bag: Start in then 80 mL/hr until infusion mL/h	nfusion rate at 10 mL/hr for 15 minutes, then increase to 20 mL/hr for 15 minutes, 5 minutes, then 80 mL/hr for 15 minutes, then 150 mL/hr for 15 minutes, then sion complete.  nfusion rate at 20 mL/hr for 15 minutes, then increase to 40 mL/hr for 15 minutes, 5 minutes, then 160 mL/hr for 15 minutes, then 300 mL/hr for 15 minutes, then sion complete.  e over 60 min at a rate up to 550 mL/hr, depending on volume of bag. May be if patient agrees and received at least 4 consecutive infliximab (or biosimilar) urs with no evidence of infusion reaction. Document qualifications prior to 0 min rapid infusion.  e over 30 min at a rate up to 1,100 mL/hr, depending on volume of bag. May be if patient agrees and received at least 4 consecutive infliximab (or biosimilar) ur with no evidence of infusion reaction. Document qualifications prior to 0 min rapid infusion.				
Provider Signature:	Date:				

Phone: \_\_\_\_\_ Fax: \_\_\_\_



# Infliximab (REMICADE) – Induction + Maintenance Infusion Therapy Plan Orders

## Page 2 of 3

Name:
Kaiser Permanente Member I.D. #
Date of Birth

Pre-Meds				
Dose: 650 mg Route: Oral Frequency: Once PRN, 30 minutes	prior to infliximab infusion (if not taken at home).			
May also be given once as needed during infusion for achiness, hea				
cetirizine (ZYRTEC) tablet	2000.10, 01.1010.1			
Dose: 10 mg Route: Oral Frequency: Once PRN, at least 30 n	ninutes prior to infliximal infusion (if not taken at			
	minutes prior to iniliximab iniusion (ii not taken at			
home).	t and the control of boundations and an action 1			
hydrocortisone sodium succinate (SOLU-CORTEF) injectable [no				
Dose: 50 mg Route: Intravenous Frequency: Once PRN, 30 r				
acetaminophen and antihistamine if patient still experiences symptom	oms with acetaminophen and antihistamine alone.			
☐ Other:				
Dose: Route: Oral Frequency: Once, 30 minute	s prior to infliximab infusion			
☐ No routine pre-medications necessary. Above pre-meds may be g	given if patient has reaction and requires pre-			
medications for future doses.				
IV Line Care				
✓ 0.9% sodium chloride infusion 250 mL				
Rate: 30 mL/hr Route: Intravenous Frequency: Run continu	lously to keep vein open			
Start peripheral IV if no central line				
Infusion Reaction Meds				
☑ albuterol (PROVENTIL) nebulizer solution 0.083%				
Dose: 2.5 mg Route: Nebulization Frequency: PRN for she	ortness of breath/wheezing			
☑ diphenhydrAMINE (BENADRYL) injectable	g			
	May repeat x1 for urticaria, pruritus, shortness of			
breath. May repeat in 15 minutes if symptoms not resolved.	may repeat X1 for difficulta, prantas, shortness of			
☑ EPINEPHrine (Epi-Pen) 0.3mg/0.3mL IM Auto-Injector				
	I for anaphylaxis. Inject into lateral thigh and hold			
for 10 seconds. Massage the injected area. Use for patients weight				
and 1.5 inch needle for patients with BMI greater than 30. Notify	/ MD if administered.			
MethylPREDNISolone Sod Succ (PF) Inj 125 mg (SOLU-Medrol P	°F).			
Dose: 125 mg Route: IV push Frequency: Once PRN for hype				
	•			
Lab Review for Nursing				
GI/Derm/Rheumatology Indications (when labs available in Epic):				
Ensure CBC, ALT, AST, and Creatinine have been drawn within to	the last 16 weeks			
If labs have not been drawn within 16 weeks, proceed with infusion and instruct patient to receive lab draw today.  **The contract of the				
<ul> <li>If patient has not had labs drawn within 20 weeks, hold infusion a</li> </ul>	and notify provider.			
Nursing Orders				
<ul> <li>Initial dose only: Verify PPD or quantiFERON-TB assay for latent</li> </ul>	t TB results are negative for TB Verify HBV sAg			
and cAb labs have been completed by the ordering provider. Do				
sAg, and HBV cAb results. Notify provider if positive result.	Tiot illiuse Nelviloade without negative 15, 115v			
<ul> <li>Do not administer infliximab and notify provider if patient has a te</li> </ul>				
of symptoms of acute viral or bacterial illness, or if patient is takin	g antibiotics for current infection.			
<ul> <li>Administer using a low protein-binding 0.2 micron filter.</li> </ul>				
<ul> <li>Document protocol qualifications in the Therapy Plan if patient wi</li> </ul>	Il receive rapid infliximab infusion.			
<ul> <li>Post infusion observation time per Nursing Standard or as follows</li> </ul>	•			
hour for the first rapid 60 min and first rapid 30 min infusion, and				
·	•			
<ul> <li>Discontinue IV line when therapy complete and patient stabilized.</li> </ul>	•			
References				
REMICADE® Prescribing Information. Revised October 2021.				
TENTION DE FRESCHIBING INTOMINATION. REVISEU OCCUBET 2021.				
Desire Of the Original Control	D. A.			
Provider Signature:	Date:			
Printed Name:	Phone: Fax:			



## Infliximab (REMICADE) – Induction + Maintenance Infusion Therapy Plan Orders

Page 3 of 3

Name:
Kaiser Permanente Member I.D. #
Date of Birth

### **Kaiser Permanente Infusion Locations**

**Bellevue Medical Center** 

11511 NE 10<sup>th</sup> St, Bellevue, WA 98004 Fax: 425-502-3811 Phone: 425-502-3820

**Capitol Hill Medical Center** 

201 16th Ave E, Seattle WA 98112

Fax: 206-326-3624 Phone: 206-326-3180

**Everett Medical Center** 

2930 Maple St, Everett, WA 98201

Fax: 425-261-1578 Phone: 425-261-1566

**Olympia Medical Center** 

700 Lilly Road N.E., Olympia, WA 98506 **Fax: 360-923-7609 Phone: 360-923-7600**  **Riverfront Medical Center - Spokane** 

W 322 North River Drive, Spokane, WA 99201 Fax: 509-434-3184 Phone: 509-324-6464

Silverdale Medical Contex

Silverdale Medical Center

10452 Silverdale Way NW, Silverdale, WA 98383 Fax: 360-307-7421 Phone: 360-307-7316

**Tacoma Medical Center** 

209 Martin Luther King Jr Way, Tacoma, WA 98405 Fax: 253-596-3351 Phone: 253-596-3350

Provider Signature:		Date:	
Printed Name:	Phone:	Fax:	

нім